{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:10:04Z","timestamp":1752156604519,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the therapeutic efficacy of artificial liver plasma adsorption (ALPA) in patients with severe pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study enrolled 151 patients meeting severe pneumonia diagnostic criteria who were admitted to the intensive care unit at Shulan Hospital, Hangzhou, China, between January 2020 and December 2024. Participants were allocated to either: (1) the ALPA intervention group (<jats:italic>n<\/jats:italic> =\u202f56) receiving artificial liver plasma adsorption (ALPA) therapy, or (2) the control group (<jats:italic>n<\/jats:italic> =\u202f95) receiving standard treatment. This study prospectively collected comprehensive clinical data, including: (1) baseline demographic characteristics; (2) serial measurements of laboratory parameters (e.g., white blood cell count (WBC), lymphocyte percentage (LY%), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6)) at pre- and post-treatment intervals; and (3) Pneumonia Severity Index (PSI) scores at admission. Patient survival outcomes were systematically recorded, including: (1) time-to-event endpoints (overall survival duration from enrollment to death or last follow-up), and (2) clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No statistically significant differences were observed between the two groups regarding WBC, CRP, PCT, or IL-6 levels at baseline (all <jats:italic>p<\/jats:italic>\u202f\u2265\u202f0.05). However, the LY% in the artificial liver treatment group was significantly lower compared to the conventional therapy group (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). Post-treatment analysis revealed that the ALPA group demonstrated significantly lower levels of WBC, LYM, CRP, PCT, and IL-6 compared to control group (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). The control group exhibited significant post-treatment elevations in WBC (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05), whereas LY%, PCT, IL-6, and CRP levels showed no significant variation (<jats:italic>p<\/jats:italic>\u202f\u2265\u202f0.05). In the ALPA group, WBC, LY%, and PCT levels remained stable (<jats:italic>p<\/jats:italic>\u202f\u2265\u202f0.05), while CRP, IL-6 demonstrated a significant reduction (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). Post-treatment mortality rates differed significantly between groups (42.9% in ALPA group versus 81.1% in controls; <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). The treatment group showed a 38.2% relative reduction in mortality compared to controls, achieving statistical significance (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). Multivariable Cox proportional hazards regression demonstrated that both elevated PSI Score at hospital admission (adjusted HR\u202f=\u202f1.009, <jats:italic>p<\/jats:italic>\u202f=\u202f0.006) and ALPA treatment (adjusted HR\u202f=\u202f4.134, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) independently predicted poorer survival outcomes. ALPA treatment was associated with significantly improved survival outcomes compared to controls (mean: 218.42 vs. 36.81\u202fdays; median not reached vs. 27.0\u202fdays; HR\u202f=\u202f0.1907, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.0001 by log-rank test).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Artificial liver plasma adsorption (ALPA) therapy demonstrates significant clinical efficacy by effectively suppressing inflammatory markers (e.g., IL-6, CRP) and attenuating cytokine storm progression. This treatment significantly reduces mortality and prolongs survival time in elderly patients with severe pneumonia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1613810","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:46:56Z","timestamp":1752126416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial liver plasma adsorption improves survival in elderly patients with severe pneumonia: a retrospective cohort study"],"prefix":"10.3389","volume":"12","author":[{"given":"Richai","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sainan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiangqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanhao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3760\/cma.j.issn.1001-0939.2016.04.005","article-title":"Diagnosis and treatment guidelines for adult community-acquired pneumonia in China","volume":"39","author":"Qu","year":"2016","journal-title":"Chin J Tuberculo Respir Dis"},{"key":"ref2","first-page":"189","article-title":"Detection and dynamic monitoring of cytokine storm predisposing factors and their preventive role in severe and critical COVID-19 cases","volume":"38","author":"Niu","year":"2020","journal-title":"Chin J Infect Dis"},{"key":"ref3","first-page":"227","article-title":"Advances to pathogenesis of influenza severe pneumonia and multiple organ dysfunction syndrome","volume":"37","author":"Xu","year":"2017","journal-title":"Int J Respir"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/mcp.0000000000000365","article-title":"Pathogenesis of severe pneumonia","volume":"23","author":"Mizgerd","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ajem.2007.10.031","article-title":"The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome","volume":"26","author":"Wang","year":"2008","journal-title":"Am J Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3760\/cma.j.issn.1674-2397.2024.01.002","article-title":"Expert consensus on artificial liver blood purification system for cytokine storm syndrome","volume":"17","year":"2024","journal-title":"Chin J Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/1744-9987.12240","article-title":"Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza a (H7N9): a cohort study","volume":"19","author":"Liu","year":"2015","journal-title":"Ther Apher Dial"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"586073","DOI":"10.3389\/fimmu.2020.586073","article-title":"The artificial-liver blood-purification system can effectively improve hypercytokinemia for COVID-19","volume":"11","author":"Guo","year":"2020","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/aor.13884","article-title":"Effect of artificial liver blood purification treatment on the survival of critical ill COVID-19 patients","volume":"45","author":"Dai","year":"2021","journal-title":"Artif Organs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3969\/j.issn.1674-9081.2013.03.018","article-title":"The application of glucocorticoids in the treatment of severe pneumonia","volume":"4","author":"Ying Yuan","year":"2013","journal-title":"Med J Peking Union Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3760\/cma.j.issn.1673-4394.2025.01.015","article-title":"Research progress on the impact of immunosenescence on the health of the elderly population","volume":"48","author":"Ruojing Bai","year":"2025","journal-title":"Int J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3760\/cma.j.cn112147-20240611-00328","article-title":"Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 edition)","volume":"48","author":"Branch","year":"2025","journal-title":"Chin J Tuberc Respir Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"8","author":"Jose","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/jarr.2002.35561","article-title":"Continuous renal replacement therapy: opinions and evidence","volume":"9","author":"Ronco","year":"2002","journal-title":"Adv Ren Replace Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MAT.0000000000001432","article-title":"Management of adult patients supported with Venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the extracorporeal life support organization (ELSO)","volume":"67","author":"Tonna","year":"2021","journal-title":"ASAIO J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1305584","article-title":"Clinical findings in 111 cases of influenza a (H7N9) virus infection","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1056\/NEJMc2011400","article-title":"Multiorgan and renal tropism of SARS-CoV-2","volume":"383","author":"Puelles","year":"2020","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"eadd4906","DOI":"10.1126\/sciimmunol.add4906","article-title":"Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19","volume":"7","author":"Laurent","year":"2022","journal-title":"Sci Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jmv.20255","article-title":"An interferon-gamma-related cytokine storm in SARS patients","volume":"75","author":"Huang","year":"2005","journal-title":"J Med Virol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.22034","article-title":"Liver: an organ with predominant innate immunity","volume":"47","author":"Gao","year":"2008","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3969\/j.issn.1671-301X.2022.04.016","article-title":"Efficacy evaluation of artificial liver blood purification system in treating 6 cases of severe pneumonia caused by novel coronavirus infection","volume":"28","author":"Peng","year":"2023","journal-title":"Lingnan J Emerg Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/039139889101400109","article-title":"Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding","volume":"14","author":"Nagaki","year":"1991","journal-title":"Int J Artif Organs"},{"key":"ref25","article-title":"The clinical efficacy of hemoperfusion in treatment of severe virai hepatitis","volume":"1","author":"Feng","year":"2002","journal-title":"Chin J Blood Purif"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.resp.2010.11.004","article-title":"Three fatal cases of pandemic 2009 influenza a virus infection in Shenzhen are associated with cytokine storm","volume":"175","author":"Cheng","year":"2011","journal-title":"Respir Physiol Neurobiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3969\/j.issn.1008-1704.2024.12.025","article-title":"Clinical study on the early application of artificial liver support therapy in HBV-ACLF patients with bacterial co-infection","volume":"29","author":"Zhong","year":"2024","journal-title":"Chin Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1613810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:37:18Z","timestamp":1752154638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1613810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":27,"alternative-id":["10.3389\/fmed.2025.1613810"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1613810","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"1613810"}}